These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 9237780)

  • 1. Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus.
    Inoue I; Takahashi K; Noji S; Awata T; Negishi K; Katayama S
    Diabetes Res Clin Pract; 1997 Jun; 36(3):143-51. PubMed ID: 9237780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study.
    Lam KS; Tiu SC; Tsang MW; Ip TP; Tam SC
    Diabetes Care; 1998 Jul; 21(7):1154-8. PubMed ID: 9653611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance.
    Laube H; Linn T; Heyen P
    Exp Clin Endocrinol Diabetes; 1998; 106(3):231-3. PubMed ID: 9710365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus?
    Scott R; Lintott CJ; Zimmet P; Campbell L; Bowen K; Welborn T
    Diabetes Res Clin Pract; 1999 Mar; 43(3):179-85. PubMed ID: 10369427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes and Acarbose Research Group.
    Costa B; Piñol C
    Diabetes Res Clin Pract; 1997 Oct; 38(1):33-40. PubMed ID: 9347244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.
    Hoffmann J; Spengler M
    Diabetes Care; 1994 Jun; 17(6):561-6. PubMed ID: 8082525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes.
    Kelley DE; Bidot P; Freedman Z; Haag B; Podlecki D; Rendell M; Schimel D; Weiss S; Taylor T; Krol A; Magner J
    Diabetes Care; 1998 Dec; 21(12):2056-61. PubMed ID: 9839094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.
    Coniff RF; Shapiro JA; Robbins D; Kleinfield R; Seaton TB; Beisswenger P; McGill JB
    Diabetes Care; 1995 Jun; 18(6):817-24. PubMed ID: 7555508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.
    Bayraktar M; Van Thiel DH; Adalar N
    Diabetes Care; 1996 Mar; 19(3):252-4. PubMed ID: 8742572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.
    Coniff RF; Shapiro JA; Seaton TB; Bray GA
    Am J Med; 1995 May; 98(5):443-51. PubMed ID: 7733122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.
    Rosak C; Hofmann U; Paulwitz O
    Diabetes Nutr Metab; 2004 Jun; 17(3):137-42. PubMed ID: 15334790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy.
    Rachman J; Levy JC; Barrow BA; Manley SE; Turner RC
    Diabetes; 1997 Oct; 46(10):1557-62. PubMed ID: 9313749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of acarbose treatment on markers of insulin sensitivity and systemic inflammation.
    Rudovich NN; Weickert MO; Pivovarova O; Bernigau W; Pfeiffer AF
    Diabetes Technol Ther; 2011 Jun; 13(6):615-23. PubMed ID: 21488802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes.
    Hanefeld M; Haffner SM; Menschikowski M; Koehler C; Temelkova-Kurktschiev T; Wildbrett J; Fischer S
    Diabetes Res Clin Pract; 2002 Mar; 55(3):221-7. PubMed ID: 11850098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of acarbose on glucose intolerance in patients with non-insulin-dependent diabetes mellitus.
    Noda K; Umeda F; Nawata H
    Diabetes Res Clin Pract; 1997 Aug; 37(2):129-36. PubMed ID: 9279483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.
    Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH; Wolever TM
    Ann Intern Med; 1994 Dec; 121(12):928-35. PubMed ID: 7734015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study.
    Hotta N; Kakuta H; Sano T; Matsumae H; Yamada H; Kitazawa S; Sakamoto N
    Diabet Med; 1993 Mar; 10(2):134-8. PubMed ID: 8458189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects on serum lipids in noninsulin dependent diabetics by acarbose treatment.
    Leonhardt W; Hanefeld M; Fischer S; Schulze J; Spengler M
    Arzneimittelforschung; 1991 Jul; 41(7):735-8. PubMed ID: 1772463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes.
    Salman S; Salman F; Satman I; Yilmaz Y; Ozer E; Sengül A; Demirel HO; Karşidağ K; Dinççağ N; Yilmaz MT
    Curr Med Res Opin; 2001; 16(4):296-306. PubMed ID: 11268714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone.
    Hanefeld M; Fischer S; Schulze J; Spengler M; Wargenau M; Schollberg K; Fücker K
    Diabetes Care; 1991 Aug; 14(8):732-7. PubMed ID: 1954810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.